Pfizer COVID-19 Vaccine Sales Drop After CDC Narrows Guidance

Revenue declined by 7 percent in the third quarter, compared to Q3 2024.

A nurse holds a COVID-19 vaccine in Miami, Fla., in this file photograph. Joe Raedle/Getty Images

Pfizer reported a decline in revenue on Nov. 4, which it primarily attributed to lower sales for the company’s COVID-19 vaccine, Comirnaty, and COVID-19 drug, Paxlovid.

The company said it made $16.7 billion in revenue in the third quarter, down 7 percent from Q3 2024.